Design Therapeutics, Inc. Related Party Transaction, Expenses from Transactions with Related Party
Design Therapeutics, Inc. (DSGN) reported Related Party Transaction, Expenses from Transactions with Related Party of $259.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty · last filed 2023-05-09
- Design Therapeutics, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2023-03-31 was $259.00K, a 19.91% increase year-over-year.
- Design Therapeutics, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-12-31 was $254.00K, a 17.05% increase year-over-year.
- Design Therapeutics, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-09-30 was $264.00K, a 169.39% increase year-over-year.
- Design Therapeutics, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-06-30 was $226.00K, a 402.22% increase year-over-year.
- Design Therapeutics, Inc. related party transaction, expenses from transactions with related party for fiscal 2022 was $960.00K, a 137.04% increase from fiscal 2021.
- Design Therapeutics, Inc. related party transaction, expenses from transactions with related party for fiscal 2021 was $405.00K, a 664.15% increase from fiscal 2020.
- Design Therapeutics, Inc. related party transaction, expenses from transactions with related party for fiscal 2020 was $53.00K.
| Period end | Related Party Transaction, Expenses from Transactions with Related Party 3 month | Related Party Transaction, Expenses from Transactions with Related Party 6 month | Related Party Transaction, Expenses from Transactions with Related Party 9 month | Related Party Transaction, Expenses from Transactions with Related Party 12 month |
|---|---|---|---|---|
| 2023-03-31 | $259.00K 10-Q · filed 2023-05-09 | $513.00K derived: sum of 2 quarters · filed 2023-05-09 | $777.00K derived: sum of 3 quarters · filed 2023-05-09 | $1.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $518.00K derived: sum of 2 quarters · filed 2023-03-14 | $744.00K derived: sum of 3 quarters · filed 2023-03-14 | $960.00K 10-K · filed 2023-03-14 |
| 2022-09-30 | $264.00K 10-Q · filed 2022-11-03 | $490.00K derived: sum of 2 quarters · filed 2022-11-03 | $706.00K 10-Q · filed 2022-11-03 | $923.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | $226.00K 10-Q · filed 2022-08-08 | $442.00K 10-Q · filed 2022-08-08 | $659.00K derived: sum of 3 quarters · filed 2023-05-09 | $757.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | $216.00K 10-Q · filed 2023-05-09 | $433.00K derived: sum of 2 quarters · filed 2023-05-09 | $531.00K derived: sum of 3 quarters · filed 2023-05-09 | $576.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $217.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $315.00K derived: sum of 2 quarters · filed 2023-03-14 | $360.00K derived: sum of 3 quarters · filed 2023-03-14 | $405.00K 10-K · filed 2023-03-14 |
| 2021-09-30 | $98.00K 10-Q · filed 2022-11-03 | $143.00K derived: sum of 2 quarters · filed 2022-11-03 | $188.00K 10-Q · filed 2022-11-03 | $233.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $45.00K 10-Q · filed 2022-08-08 | $90.00K 10-Q · filed 2022-08-08 | $135.00K derived: sum of 3 quarters · filed 2022-08-08 | $135.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $45.00K 10-Q · filed 2022-05-09 | $90.00K derived: sum of 2 quarters · filed 2022-05-09 | $90.00K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $45.00K derived: sum of 2 quarters · filed 2022-03-10 | $53.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | $8.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |